An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
Maria Sole Chimenti,1,* Arianna D’Antonio,1,* Paola Conigliaro,1 Sara Ferrigno,1 Andrea Vendola,1 Mario Ferraioli,1 Paola Triggianese,1 Luisa Costa,2 Francesco Caso,2 Roberto Perricone1 1Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome T...
Enregistré dans:
Auteurs principaux: | Chimenti MS, D'Antonio A, Conigliaro P, Ferrigno S, Vendola A, Ferraioli M, Triggianese P, Costa L, Caso F, Perricone R |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/9c4966ba5d5b4b01b44f285dac251f29 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
par: Ly K, et autres
Publié: (2019) -
The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice
par: Georgios Kokolakis, et autres
Publié: (2021) -
Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
par: D'Angelo S, et autres
Publié: (2017) -
Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients
par: Song Zhang, et autres
Publié: (2021) -
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
par: Harrington R, et autres
Publié: (2020)